English
Arabic
Chinese (Simplified)
Dutch
Esperanto
French
German
Greek
Italian
Japanese
Korean
Portuguese
Russian
Spanish
UrduThe 8th annual Utah Cardiac Recovery Symposium (U-CARS) will host thought leaders and noted speakers from around the globe to discuss ground-breaking research in the field of cardiac recovery.
Tag: Heart Failure
Genetic Breakthrough Identifies Heart Failure Risk in African and Latino Americans
Findings may inform genetic screening test for patients at risk and medically under-served
Genetic Variant Largely Found in Patients of African Descent Increases Risk for Heart Failure
A genetic variant in the gene transthyretin (TTR) is a more significant cause of heart failure than previously believed. The study also revealed that a disease caused by this genetic variant, called hereditary transthyretin amyloid cardiomyopathy, is significantly underdiagnosed.
Stem Cell Therapy Helps Broken Hearts Heal in Unexpected Way
A study in Nature shows stem cell therapy helps hearts recover from a heart attack, although not for the biological reasons originally proposed two decades ago that today are the basis of ongoing clinical trials. The study reports that injecting living or even dead heart stem cells into the injured hearts of mice triggers an acute inflammatory process, which in turn generates a wound healing-like response to enhance the mechanical properties of the injured area.
Probing the role of an inflammation resolution sensor in obesity and heart failure
After heart attack, ALX/FPR2 is activated by resolvin D1 in immune cells in the spleen and at the heart attack site. This speeds resolution of the heart injury. Research with mice that completely lack ALX/FPR2 reveals more about the pathways this resolution sensor uses to target inflammation.
Researchers Discover New Mutations in Gene Associated with Disease That Causes Weakening of the Heart
Researchers from the Intermountain Healthcare Heart Institute in Salt Lake City have identified new mutations in a gene commonly associated with non-ischemic dilated cardiomyopathy (NIDC), a disease that weakens the heart muscle, making it more difficult to adequately circulate blood to meet the body’s needs.
Artificial Intelligence Tool Predicts Life Expectancy in Heart Failure Patients
Researchers at University of California San Diego School of Medicine, as well as a diverse team of cardiologists and physicists, developed a machine learning algorithm to predict the life expectancy in heart failure patients.
CLEVELAND CLINIC UNVEILS TOP 10 MEDICAL INNOVATIONS FOR 2020
A dual-acting osteoporosis drug. Minimally invasive mitral valve surgery. New treatment for peanut allergies. These are some of the innovations that will enhance healing and change healthcare in the coming year, according to a distinguished panel of doctors and researchers.
Pairing New Medications Could Offer Hope to Heart Disease Patients
Cardiologist Bertram Pitt, MD, sees promise in combining two new classes of medication into a treatment regimen for patients with cardiovascular disease. Pitt will discuss the advantages of this treatment plan in his plenary lecture at an American Physiological Society Conference in Estes Park, Colo.
Heart failure and the obesity paradox
While obesity significantly increases your chances of developing heart failure, for those with established heart failure it may confer a survival benefit compared with normal weight or underweight individuals.
First Patient Enrolled in Novel Stem Cell Trial for Heart Failure Treatment
MedStar Heart & Vascular Institute has enrolled its first patient to a clinical trial to determine whether cardiac stem cells reduce inflammation enough to improve heart function in patients with heart failure severe enough to require a left ventricular assist device, or LVAD.
Three-Year COAPT Data Demonstrates Continued Safety and Effectiveness in Patients with Heart Failure and Secondary Mitral Regurgitation
The three-year results from the COAPT trial demonstrated that reducing severe secondary mitral regurgitation (SMR) with the MitraClip device safely improves prognosis in selected heart failure (HF) patients. In addition, those patients that crossed over and received the MitraClip after 24 months showed the same benefits as those who received the device at the beginning of the study. Two-year data were presented at TCT 2018 and published in the New England Journal of Medicine.
Cheaper Drug Just As Effective Protecting Heart in Duchenne Muscular Dystrophy
A new clinical trial conducted at The Ohio State University Wexner Medical Center found a cost-effective generic medication works just as well as a more expensive drug in preserving cardiovascular function in boys with Duchenne muscular dystrophy (DMD).
Improving Doctor-Patient Communication at the End of Life: Multi-Center Study Suggests It Can Be Done
To find out whether an intervention could increase the number of discussions between clinicians and patients with heart failure about the kinds of treatments they would want at the end of their lives, also known as advance care planning, researchers at The Mount Sinai Hospital developed a rigorous six-center study to investigate a novel communication intervention. The study appears in the Journal of the American College of Cardiology.
A Bathroom Scale Could Monitor Millions with Heart Failure
Millions of heart failure patients are readmitted to hospital every few months to adjust medications. It sends medical costs sky-high and burdens patients’ lives. A new bathroom scale could give clinicians health data they need to preempt hospitalizations and treat patients remotely.
Announcing the TCT 2019 Late-Breaking Trials and Science
The Cardiovascular Research Foundation (CRF) has announced the 12 late-breaking trials and 16 late-breaking science presentations that will be reported at the Transcatheter Cardiovascular Therapeutics (TCT) 2019 scientific symposium. TCT, the world’s premier educational meeting specializing in interventional cardiovascular medicine, will take place September 25 – 29, 2019 at The Moscone Center in San Francisco, California.